The human insulin analogue insulin lispro

Annals of Medicine

Volumn 30, Issue 3, 1998, Pages 260-266

  Koivisto, Veikko A ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Diabetes; Hypoglycaemia; Insulin lispro; Insulin pharmacokinetics; Insulin resistance; Physical exercise

Indexed keywords

AMINO ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; LYSINE; PROLINE;

ARTICLE; DIABETES MELLITUS; DRUG ABSORPTION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MEAL; PATIENT SATISFACTION; PHYSICAL ACTIVITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

EID: 0031746298     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899809005853     Document Type: Article

References (32)

1. Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349:47-51.
2. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997; 337: 176-83.
3. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analog of human insulin. Diabetes 1994; 43: 396-402.
4. ter Braak EW, Woodworth JR, Bianchi R, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996; 19: 1437-40.
5. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19: 62-72.
6. Anderson JH Jr, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypo-glycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46: 265-70.
7. Anderson JH Jr, Brunelle R, Keohane P, et al. Insulin analogue improves mealtime treatment of NIDDM patients. Arch Intern Med 1997; 157: 1249-55.
8. Holcombe J, Zalani S, Arora V. Comparative study of insulin lispro and regular human insulin in 481 adolescents with type 1 diabetes. Diabetologia 1997; 40 (Suppl 1): A344.
9. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997; 46: 440-3.
10. El-Ghazali S, Akram J, Al-Maatouq M. Management of diabetes mellitus during the holy month of Ramadan. Proceedings of an International Symposium. Practical Diabetes International 1998; 15: S17-S20.
11. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro induced hypoglycemia in IDDM. Diabetes Care 1997; 20: 152-5.
12. Schernthaner G, Wein W, Sandholzer K, Equiliz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro: a new therapeutic option for type 1 diabetic patients. Diabetes Care 1998; 21: 570-3.
13. Holleman F, van den Brand JJG, Hoven RARA, et al. Comparison of Lys B28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19: 1426-9.
14. 1c without increasing hypoglycemia risk in diabetic patients treated with insulin lispro in external pumps. Diabetologia 1997; 40 (Suppl 1): A10.
15. Ebeling P, Jansson PA, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287-9.
16. Ebeling P, Jansson P-A, Smith U, et al. Optimal combination of insulin lispro and basal insulin improves glycemic control in IDDM. Diabetologia 1997; 40 (Suppl 1): A351.
17. Zinman B, Ross S, Campos R, Strack T. A double blind randomized controlled trial comparing NPH and Ultralente as basal insulin replacement with lispro insulin. The Canadian Lispro Study Group. Diabetes 1997; 46 (Suppl 1): 43A.
18. Bastyr EJ III, Holcombe J, Andersen JH, Clore JN. Mixing insulin lispro with ultralente insulin. Diabetes Care 1997; 20: 1047-8.
19. Feinglos MN, Thacker CH, English J, Bethel MA, Lane J. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997; 20: 1539-42.
20. The Diabetes Control and Complications Trial Research Group. The absence of glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-98.
21. Torlone E, Fanelli C, Rambotti AM, et al. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 1994; 37: 713-20.
22. Frier BM. Symptomatic and physiological responses to hypoglycaemia induced by human soluble insulin and the insulin analogue lispro human insulin. Diabet Med 1997; 14: 929-36.
23. Brunelle RL, Llewelyn J, Vignati L, Anderson J, Koivisto VA. Humalog reduces the incidence of severe hypoglycemia in IDDM patients. Diabetologia 1997; 40 (Suppl 1): A352.
24. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20: 1827-32.
25. Tuominen JA, Karonen SL, Melamies L, Bolli G, Koivisto VA. Exercise-induced hypoglycemia in IDDM patients treated with a short-acting insulin analogue. Diabetologia 1995; 38: 106-11.
26. Rönnemaa T, Viikari J. Reduction of snacks when switching IDDM patients from regular insulin to lispro insulin. Diabetologia 1997; 40 (Suppl 1): A350.
27. Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S. Immunologic effects of insulin lispro [Lys(B28), Pro(B29) human insulin] in IDDM and NIDDM patients previously treated with insulin. Diabetes 1996; 45: 1750-4.
28. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe insulin antibody-mediated human insulin resistance: successful treatment with the insulin analog lispro. Diabetes Care 1997; 20: 71-3.
29. Henrichs HR, Unger H, Trautmann ME, Pfützer A. Severe insulin resistance treated with insulin lispro. Lancet 1996; 348: 1248.
30. Kumar D. Lispro analog for treatment of generalized allergy to human insulin. Diabetes Care 1997: 20: 1357-9.
31. Diamond T, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009.
32. Kotsanos JG, Vignati L, Huster W, et al. Health-related quality of life results from multinational clinical trials of insulin lispro. Diabetes Care 1997; 20: 948-58.